EUVIMEDEUVIMED entdecken
Open Access

Tmem39b promotes tumor progression and sorafenib resistance by inhibiting ferroptosis in hepatocellular carcinoma

Ming Zhuang, Xue Zhang, L U Li, Liming Wen, Jiamin Qin

Oncology Research · 2024

DOI: 10.32604/or.2024.046170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2024. Verfasst von Ming Zhuang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Sichuan Mianyang 404 Hospital, Mianyang, 621000, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Sorafenib, Ferroptosis, Liver Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularSorafenibFerroptosisLiver NeoplasmsDrug Resistance, NeoplasmMembrane ProteinsDisease ProgressionHumansCell Line, TumorMiceAnimalsAntineoplastic AgentsPrognosisGene Expression Regulation, NeoplasticMaleXenograft Model Antitumor AssaysFemale

Stichwörter der Autor:innen

FerroptosisHepatocellular carcinomaSorafenibTMEM39b

Substanzen

SorafenibMembrane ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Sichuan Mianyang 404 Hospital, Mianyang, 621000, China.

Zitieren

APA

Zhuang, M., Zhang, X., Li, L. U., Wen, L., & Qin, J. (2024). Tmem39b promotes tumor progression and sorafenib resistance by inhibiting ferroptosis in hepatocellular carcinoma. Oncology Research. https://doi.org/10.32604/or.2024.046170

Vancouver

Zhuang M, Zhang X, Li LU, Wen L, Qin J. Tmem39b promotes tumor progression and sorafenib resistance by inhibiting ferroptosis in hepatocellular carcinoma. Oncology Research. 2024. doi:10.32604/or.2024.046170

BibTeX
@article{Zhuang2024,
  author = {Zhuang, Ming and Zhang, Xue and Li, L U and Wen, Liming and Qin, Jiamin},
  title = {Tmem39b promotes tumor progression and sorafenib resistance by inhibiting ferroptosis in hepatocellular carcinoma},
  journal = {Oncology Research},
  year = {2024},
  doi = {10.32604/or.2024.046170}
}
Kostenlos starten →